Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MGB Biopharma has inked an agreement with Almac's Sciences Business Unit, as per which Almac will manufacture the production of MGB's gram positive antibacterial compound MGB-BP3.
Subscribe to our email newsletter
The compound which is a DNA minor groove binder is currently in pre-clinical development with IND filing targeted for the third quarter of 2012.
Almac Operations VP Rick Dyer said with their expertise in early phase clinical development, the company is happy to take up this phase of work for MGB Biopharma.
The Almac Group is known for providing services in R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply and IXRStechnology (IVRS/IWRS), besides commercial-scale manufacture.